While ponatinib is effective in treating specific hematological malignancies, it may also induce a variety of adverse reactions.
I. Major Side Effects
1. Severe Adverse Reactions
High-risk severe side effects requiring close monitoring of ponatinib are as follows:
(1) Arterial occlusive events: Potentially fatal complications including myocardial infarction, stroke, large intracranial artery stenosis, and severe peripheral vascular disease, which may require urgent revascularization. Such events can occur in patients with or without cardiovascular risk factors, including those under 50 years of age.
(2) Venous thromboembolic events: Including deep vein thrombosis, pulmonary embolism, retinal vein occlusion, etc.
(3) Heart failure: Life-threatening condition; signs of heart failure require regular monitoring.
(4) Hepatotoxicity: May lead to hepatic failure and death. Fulminant hepatic failure has been reported in patients within one week of treatment initiation.
2. Common Adverse Reactions (Incidence > 20%)
(1) Monotherapy: Rash, arthralgia, abdominal pain, fatigue, headache, constipation, hypertension, dry skin, hepatotoxicity, fluid retention and edema, pyrexia, pancreatitis/increased lipase levels, nausea, hemorrhage, anemia, arterial occlusive events, arrhythmia.
(2) Combination chemotherapy: Hepatotoxicity, arthralgia, rash, headache, pyrexia, abdominal pain, constipation, fatigue, nausea, oral mucositis, hypertension, pancreatitis/increased lipase levels, peripheral neuropathy, hemorrhage, febrile neutropenia, fluid retention and edema, vomiting, paresthesia, arrhythmia.
3. Other Notable Side Effects
Hypertension, pancreatitis, peripheral neuropathy, ocular toxicity, hemorrhage, myelosuppression.
II. Methods to Alleviate Side Effects
1. Dosage Adjustment Strategies
The FDA recommends the following dosage adjustment regimens based on the severity of adverse reactions:
(1) Arterial occlusive events (cardiovascular/cerebrovascular)
Grade 1: Suspend treatment, resume at the original dose upon resolution.
Grade 2: Suspend treatment, escalate to Grade 0–1, then reduce the dose by one level.
Recurrent Grade 3–4 events: Permanent discontinuation.
(2) Heart failure (Grade 2–3)
Suspend treatment until recovery to Grade 0–1, then reduce the dose by one level; discontinue permanently upon recurrence.
(3) Hepatotoxicity (AST/ALT > 3×ULN)
Suspend treatment until recovery to Grade 0–1, then reduce the dose by one level.
Permanent discontinuation if concurrent bilirubin > 2×ULN and alkaline phosphatase < 2×ULN.
(4) Pancreatitis/increased lipase levels
Suspend treatment, reduce dosage, or permanently discontinue according to severity.
(5) Myelosuppression (ANC < 1×10⁹/L or platelet count < 50×10⁹/L)
Suspend treatment until ANC ≥ 1.5×10⁹/L and platelet count ≥ 75×10⁹/L, then resume at the original dose; reduce dosage by one level upon recurrence.
2. Lifestyle Management
(1) Maintain adequate hydration to reduce the risk of tumor lysis syndrome.
(2) Seek immediate medical evaluation for pancreatitis screening upon onset of abdominal pain, nausea or vomiting.
(3) Emergency medical attention is required immediately for thrombotic symptoms such as chest pain, dyspnea, limb weakness, and speech disturbance.
(4) Discontinue the medication at least 1 week prior to elective surgery. Treatment may be resumed no earlier than 2 weeks post-surgery with complete wound healing.
III. Storage Requirements
1. Temperature Specifications
Ponatinib tablets should be stored at room temperature between 20°C and 25°C. Short-term storage at 15°C to 30°C is permissible, complying with USP controlled room temperature criteria.
2. Packaging and Placement
(1) The product is packed in high-density polyethylene bottles with a desiccant canister and child-resistant induction-sealed caps. Keep the cap tightly closed to prevent moisture absorption.
(2) Keep all medication out of reach of children.
3. Additional Precautions
(1) Do not store in humid environments such as bathrooms or kitchens.
(2) Avoid direct sunlight exposure.
(3) Do not use expired medication. Dispose of expired drugs properly in accordance with local regulations.
(4) Preferably carry the original drug container during travel, and avoid exposure to extreme temperatures.
